Literature DB >> 19319830

It's a choice to move forward: women's perceptions about treatment decision making in recurrent ovarian cancer.

L Elit1, C Charles, S Dimitry, S Tedford-Gold, A Gafni, I Gold, T Whelan.   

Abstract

OBJECTIVE: This research explores the treatment decision-making (TDM) experiences of women with recurrent ovarian cancer (ROC) with regard to treatment options; their understanding of risks and benefits of various treatment options; the decision-making role they want for themselves and for their oncologist; and the social context of the consultation as it pertains to the decision.
METHODS: We conducted semi-structured interviews with 26 women at the time of first recurrence. Through inductive data analysis key themes were identified.
RESULTS: Many women describe self-identifying the cancer recurrence fairly quickly due to new symptoms. Many feel that the goal for treating their recurrence is to control versus cure the cancer. They describe the subsequent process of diagnosis and TDM for ROC as quick and straightforward with all women accepting the oncologists' treatment recommendation. They feel that the type and number of treatment options are limited. They have a strong desire for physician continuity in their care. Participants feel that their doctor's recommendations as well as their previous experience with ovarian cancer are strong factors influencing their current TDM process.
CONCLUSIONS: Shared decision making is based on a simultaneous participation of both the physician and patient in TDM. When faced with ROC, women feel that their doctor's recommendation and their past experience with treatment and TDM are prominent factors influencing the current TDM process.

Entities:  

Mesh:

Year:  2010        PMID: 19319830     DOI: 10.1002/pon.1562

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.894


  8 in total

1.  Walking a tightrope: oncologists' perspective on providing information to women with recurrent ovarian cancer (ROC) during the medical encounter.

Authors:  Laurie Elit; Cathy Charles; Amiram Gafni; Jennifer Ranford; Sara Tedford Gold; Irving Gold
Journal:  Support Care Cancer       Date:  2011-12-14       Impact factor: 3.603

Review 2.  Post-traumatic stress disorder and cancer.

Authors:  Matthew J Cordova; Michelle B Riba; David Spiegel
Journal:  Lancet Psychiatry       Date:  2017-01-19       Impact factor: 27.083

3.  One step at a time: self-management and transitions among women with ovarian cancer.

Authors:  Dena Schulman-Green; Elizabeth H Bradley; Nicholas R Nicholson; Erin George; Allie Indeck; Ruth McCorkle
Journal:  Oncol Nurs Forum       Date:  2012-07       Impact factor: 2.172

4.  Ovarian cancer survivors' experiences of self-advocacy: a focus group study.

Authors:  Teresa L Hagan; Heidi S Donovan
Journal:  Oncol Nurs Forum       Date:  2013-03       Impact factor: 2.172

5.  Disparities in use of gynecologic oncologists for women with ovarian cancer in the United States.

Authors:  Shamly Austin; Michelle Y Martin; Yongin Kim; Ellen M Funkhouser; Edward E Partridge; Maria Pisu
Journal:  Health Serv Res       Date:  2012-12-03       Impact factor: 3.402

Review 6.  A new paradigm for clinical communication: critical review of literature in cancer care.

Authors:  Peter Salmon; Bridget Young
Journal:  Med Educ       Date:  2016-12-20       Impact factor: 6.251

7.  Patients' preferences for participation in treatment decision-making at the end of life: qualitative interviews with advanced cancer patients.

Authors:  Linda Brom; H Roeline W Pasman; Guy A M Widdershoven; Maurice J D L van der Vorst; Jaap C Reijneveld; Tjeerd J Postma; Bregje D Onwuteaka-Philipsen
Journal:  PLoS One       Date:  2014-06-25       Impact factor: 3.240

8.  Patient, physician, and caregiver perspectives on ovarian cancer treatment decision making: lessons from a qualitative pilot study.

Authors:  Rachel Pozzar; Laura-Mae Baldwin; Barbara A Goff; Donna L Berry
Journal:  Pilot Feasibility Stud       Date:  2018-07-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.